36555-52-9 Usage
General Description
(E)-2-(hydroxyimino)acetaldehyde is a chemical compound with the formula C3H5NO2. It is a building block for the synthesis of various organic compounds and is commonly used in the pharmaceutical and agricultural industries. (E)-2-(hydroxyiMino)acetaldehyde is also used as an intermediate in the production of heterocyclic compounds and is a key starting material in the synthesis of drugs and agrochemicals. (E)-2-(hydroxyimino)acetaldehyde is known for its potential applications in medicinal chemistry and is utilized in the development of new therapeutic agents. Additionally, it has been studied for its antioxidant and antibacterial properties, making it a valuable compound in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 36555-52-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,5,5 and 5 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 36555-52:
(7*3)+(6*6)+(5*5)+(4*5)+(3*5)+(2*5)+(1*2)=129
129 % 10 = 9
So 36555-52-9 is a valid CAS Registry Number.
36555-52-9Relevant articles and documents
Preparation of 1-Methylimidazole- N-oxide (NMI-O)
Murray, James I.,Spivey, Alan C.
, p. 331 - 340 (2017/06/08)
-
Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers
Wu, Shengde,Fluxe, Andrew,Janusz, John M.,Sheffer, James B.,Browning, Greg,Blass, Benjamin,Cobum, Keith,Hedges, Richard,Murawsky, Michael,Fang, Bin,Fadayel, Gina M.,Hare, Michelle,Djandjighian, Laurent
, p. 5859 - 5863 (2007/10/03)
A novel class of tetrahydroindolone-derived semicarbazones has been discovered as potent Kv1.5 blockers. In in vitro studies, several compounds exhibited very good potency for blockade of Kv1.5. Compound 8i showed good selectivity for blockade of Kv1.5 vs hERG and L-type calcium channels. In an anesthetized pig model, compounds 8i and 10c increased atrial ERP about 28%, 18%, respectively, in the right atrium without affecting ventricular ERP.
